Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...

The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...

Psoriasis is a chronic, immune-mediated skin condition driven by the IL-23/Th17 pathway, characterized by elevated CCL20 and CCR6-positive cells in affected skin.1 There is a significant need for oral ...

VANCOUVER, BC, Dec. 31, 2025 /CNW/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035([1]) , driven by a fundamental shift in cancer ...

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...

News of Schlossberg’s death arrived via the John F. Kennedy Library Foundation’s Instagram page, as she was the late ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

When a new permanent blood donation centre opened in Brighton city centre, I thought it was the perfect opportunity to take ...

First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries - Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) ...

Learn more about whether Charles River Laboratories International, Inc. or Illumina, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics ...

LED face masks are one of skincare’s biggest at-home innovations, bringing light therapy – once limited to clinics – into our ...